nodes	percent_of_prediction	percent_of_DWPC	metapath
Ticagrelor—ABCB1—hematologic cancer	0.185	1	CbGaD
Ticagrelor—ABCB1—Lenalidomide—hematologic cancer	0.0348	0.0698	CbGbCtD
Ticagrelor—CYP3A4—Bexarotene—hematologic cancer	0.0208	0.0418	CbGbCtD
Ticagrelor—ABCB1—Daunorubicin—hematologic cancer	0.0204	0.0409	CbGbCtD
Ticagrelor—ABCB1—Alitretinoin—hematologic cancer	0.02	0.0401	CbGbCtD
Ticagrelor—CYP3A4—Busulfan—hematologic cancer	0.0194	0.0389	CbGbCtD
Ticagrelor—CYP3A4—Lomustine—hematologic cancer	0.0194	0.0389	CbGbCtD
Ticagrelor—CYP3A4—Thiotepa—hematologic cancer	0.0173	0.0347	CbGbCtD
Ticagrelor—ABCB1—Imatinib—hematologic cancer	0.0156	0.0313	CbGbCtD
Ticagrelor—ABCB1—Nilotinib—hematologic cancer	0.0142	0.0285	CbGbCtD
Ticagrelor—ABCB1—Vinorelbine—hematologic cancer	0.0141	0.0282	CbGbCtD
Ticagrelor—CYP3A4—Methoxsalen—hematologic cancer	0.0134	0.027	CbGbCtD
Ticagrelor—CYP3A4—Bortezomib—hematologic cancer	0.0128	0.0256	CbGbCtD
Ticagrelor—ABCB1—Dasatinib—hematologic cancer	0.0125	0.0252	CbGbCtD
Ticagrelor—ABCB1—Mitoxantrone—hematologic cancer	0.0124	0.0249	CbGbCtD
Ticagrelor—CYP3A4—Daunorubicin—hematologic cancer	0.0122	0.0245	CbGbCtD
Ticagrelor—ABCB1—Betamethasone—hematologic cancer	0.011	0.0222	CbGbCtD
Ticagrelor—ABCB1—Gemcitabine—hematologic cancer	0.0109	0.022	CbGbCtD
Ticagrelor—ABCB1—Prednisolone—hematologic cancer	0.0109	0.0219	CbGbCtD
Ticagrelor—CYP3A4—Cytarabine—hematologic cancer	0.0108	0.0216	CbGbCtD
Ticagrelor—CYP3A4—Teniposide—hematologic cancer	0.0106	0.0213	CbGbCtD
Ticagrelor—ABCB1—Prednisone—hematologic cancer	0.0103	0.0207	CbGbCtD
Ticagrelor—CYP3A4—Ifosfamide—hematologic cancer	0.00979	0.0197	CbGbCtD
Ticagrelor—ABCB1—Irinotecan—hematologic cancer	0.00975	0.0196	CbGbCtD
Ticagrelor—CYP3A4—Imatinib—hematologic cancer	0.00935	0.0188	CbGbCtD
Ticagrelor—CYP3A4—Ruxolitinib—hematologic cancer	0.00881	0.0177	CbGbCtD
Ticagrelor—ABCB1—Vinblastine—hematologic cancer	0.00867	0.0174	CbGbCtD
Ticagrelor—ABCB1—Vincristine—hematologic cancer	0.00852	0.0171	CbGbCtD
Ticagrelor—CYP3A4—Nilotinib—hematologic cancer	0.0085	0.0171	CbGbCtD
Ticagrelor—CYP3A4—Vinorelbine—hematologic cancer	0.00843	0.0169	CbGbCtD
Ticagrelor—ABCB1—Cisplatin—hematologic cancer	0.00795	0.016	CbGbCtD
Ticagrelor—ABCB1—Etoposide—hematologic cancer	0.00781	0.0157	CbGbCtD
Ticagrelor—CYP3A4—Triamcinolone—hematologic cancer	0.00771	0.0155	CbGbCtD
Ticagrelor—CYP3A4—Dasatinib—hematologic cancer	0.00751	0.0151	CbGbCtD
Ticagrelor—CYP3A4—Mitoxantrone—hematologic cancer	0.00742	0.0149	CbGbCtD
Ticagrelor—CYP3A4—Betamethasone—hematologic cancer	0.00661	0.0133	CbGbCtD
Ticagrelor—CYP3A4—Prednisolone—hematologic cancer	0.00653	0.0131	CbGbCtD
Ticagrelor—ABCB1—Dexamethasone—hematologic cancer	0.00642	0.0129	CbGbCtD
Ticagrelor—CYP3A4—Prednisone—hematologic cancer	0.00616	0.0124	CbGbCtD
Ticagrelor—CYP3A4—Irinotecan—hematologic cancer	0.00584	0.0117	CbGbCtD
Ticagrelor—ABCB1—Doxorubicin—hematologic cancer	0.00533	0.0107	CbGbCtD
Ticagrelor—CYP3A4—Vinblastine—hematologic cancer	0.00519	0.0104	CbGbCtD
Ticagrelor—ABCB1—Methotrexate—hematologic cancer	0.00516	0.0104	CbGbCtD
Ticagrelor—CYP3A4—Vincristine—hematologic cancer	0.00511	0.0103	CbGbCtD
Ticagrelor—CYP3A4—Etoposide—hematologic cancer	0.00468	0.0094	CbGbCtD
Ticagrelor—CYP3A4—Dexamethasone—hematologic cancer	0.00385	0.00773	CbGbCtD
Ticagrelor—CYP3A4—Doxorubicin—hematologic cancer	0.00319	0.00641	CbGbCtD
Ticagrelor—Body temperature increased—Etoposide—hematologic cancer	3.59e-05	0.000138	CcSEcCtD
Ticagrelor—Abdominal pain—Etoposide—hematologic cancer	3.59e-05	0.000138	CcSEcCtD
Ticagrelor—Vertigo—Prednisone—hematologic cancer	3.58e-05	0.000138	CcSEcCtD
Ticagrelor—Haemorrhage—Epirubicin—hematologic cancer	3.58e-05	0.000138	CcSEcCtD
Ticagrelor—Eye disorder—Methotrexate—hematologic cancer	3.58e-05	0.000138	CcSEcCtD
Ticagrelor—Syncope—Prednisone—hematologic cancer	3.58e-05	0.000138	CcSEcCtD
Ticagrelor—Vomiting—Vincristine—hematologic cancer	3.56e-05	0.000137	CcSEcCtD
Ticagrelor—Asthenia—Cisplatin—hematologic cancer	3.56e-05	0.000137	CcSEcCtD
Ticagrelor—Cardiac disorder—Methotrexate—hematologic cancer	3.55e-05	0.000137	CcSEcCtD
Ticagrelor—Fatigue—Triamcinolone—hematologic cancer	3.55e-05	0.000137	CcSEcCtD
Ticagrelor—Urinary tract disorder—Epirubicin—hematologic cancer	3.54e-05	0.000136	CcSEcCtD
Ticagrelor—Rash—Vincristine—hematologic cancer	3.53e-05	0.000136	CcSEcCtD
Ticagrelor—Dermatitis—Vincristine—hematologic cancer	3.53e-05	0.000136	CcSEcCtD
Ticagrelor—Oedema peripheral—Epirubicin—hematologic cancer	3.53e-05	0.000136	CcSEcCtD
Ticagrelor—Haematuria—Doxorubicin—hematologic cancer	3.52e-05	0.000136	CcSEcCtD
Ticagrelor—Connective tissue disorder—Epirubicin—hematologic cancer	3.52e-05	0.000136	CcSEcCtD
Ticagrelor—Urethral disorder—Epirubicin—hematologic cancer	3.51e-05	0.000135	CcSEcCtD
Ticagrelor—Headache—Vincristine—hematologic cancer	3.51e-05	0.000135	CcSEcCtD
Ticagrelor—Loss of consciousness—Prednisone—hematologic cancer	3.5e-05	0.000135	CcSEcCtD
Ticagrelor—Hypotension—Dexamethasone—hematologic cancer	3.49e-05	0.000135	CcSEcCtD
Ticagrelor—Hypotension—Betamethasone—hematologic cancer	3.49e-05	0.000135	CcSEcCtD
Ticagrelor—Nausea—Carmustine—hematologic cancer	3.49e-05	0.000134	CcSEcCtD
Ticagrelor—Epistaxis—Doxorubicin—hematologic cancer	3.48e-05	0.000134	CcSEcCtD
Ticagrelor—Angiopathy—Methotrexate—hematologic cancer	3.47e-05	0.000134	CcSEcCtD
Ticagrelor—Vomiting—Irinotecan—hematologic cancer	3.47e-05	0.000134	CcSEcCtD
Ticagrelor—Vomiting—Mitoxantrone—hematologic cancer	3.47e-05	0.000134	CcSEcCtD
Ticagrelor—Immune system disorder—Methotrexate—hematologic cancer	3.46e-05	0.000133	CcSEcCtD
Ticagrelor—Nausea—Alitretinoin—hematologic cancer	3.46e-05	0.000133	CcSEcCtD
Ticagrelor—Mediastinal disorder—Methotrexate—hematologic cancer	3.45e-05	0.000133	CcSEcCtD
Ticagrelor—Hypertension—Prednisone—hematologic cancer	3.44e-05	0.000133	CcSEcCtD
Ticagrelor—Rash—Mitoxantrone—hematologic cancer	3.44e-05	0.000133	CcSEcCtD
Ticagrelor—Rash—Irinotecan—hematologic cancer	3.44e-05	0.000133	CcSEcCtD
Ticagrelor—Dermatitis—Irinotecan—hematologic cancer	3.44e-05	0.000133	CcSEcCtD
Ticagrelor—Dermatitis—Mitoxantrone—hematologic cancer	3.44e-05	0.000133	CcSEcCtD
Ticagrelor—Headache—Irinotecan—hematologic cancer	3.42e-05	0.000132	CcSEcCtD
Ticagrelor—Headache—Mitoxantrone—hematologic cancer	3.42e-05	0.000132	CcSEcCtD
Ticagrelor—Nausea—Ifosfamide—hematologic cancer	3.41e-05	0.000132	CcSEcCtD
Ticagrelor—Feeling abnormal—Triamcinolone—hematologic cancer	3.39e-05	0.000131	CcSEcCtD
Ticagrelor—Diarrhoea—Cisplatin—hematologic cancer	3.39e-05	0.000131	CcSEcCtD
Ticagrelor—Vomiting—Gemcitabine—hematologic cancer	3.38e-05	0.00013	CcSEcCtD
Ticagrelor—Bradycardia—Doxorubicin—hematologic cancer	3.37e-05	0.00013	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.37e-05	0.00013	CcSEcCtD
Ticagrelor—Paraesthesia—Betamethasone—hematologic cancer	3.36e-05	0.000129	CcSEcCtD
Ticagrelor—Paraesthesia—Dexamethasone—hematologic cancer	3.36e-05	0.000129	CcSEcCtD
Ticagrelor—Mental disorder—Methotrexate—hematologic cancer	3.35e-05	0.000129	CcSEcCtD
Ticagrelor—Rash—Gemcitabine—hematologic cancer	3.35e-05	0.000129	CcSEcCtD
Ticagrelor—Dermatitis—Gemcitabine—hematologic cancer	3.35e-05	0.000129	CcSEcCtD
Ticagrelor—Eye disorder—Epirubicin—hematologic cancer	3.35e-05	0.000129	CcSEcCtD
Ticagrelor—Hypersensitivity—Etoposide—hematologic cancer	3.35e-05	0.000129	CcSEcCtD
Ticagrelor—Malnutrition—Methotrexate—hematologic cancer	3.33e-05	0.000128	CcSEcCtD
Ticagrelor—Haemoglobin—Doxorubicin—hematologic cancer	3.33e-05	0.000128	CcSEcCtD
Ticagrelor—Headache—Gemcitabine—hematologic cancer	3.33e-05	0.000128	CcSEcCtD
Ticagrelor—Nausea—Vincristine—hematologic cancer	3.33e-05	0.000128	CcSEcCtD
Ticagrelor—Cardiac disorder—Epirubicin—hematologic cancer	3.32e-05	0.000128	CcSEcCtD
Ticagrelor—Haemorrhage—Doxorubicin—hematologic cancer	3.31e-05	0.000128	CcSEcCtD
Ticagrelor—Hypersensitivity—Prednisolone—hematologic cancer	3.3e-05	0.000127	CcSEcCtD
Ticagrelor—Dyspepsia—Betamethasone—hematologic cancer	3.29e-05	0.000127	CcSEcCtD
Ticagrelor—Dyspepsia—Dexamethasone—hematologic cancer	3.29e-05	0.000127	CcSEcCtD
Ticagrelor—Urinary tract disorder—Doxorubicin—hematologic cancer	3.27e-05	0.000126	CcSEcCtD
Ticagrelor—Oedema peripheral—Doxorubicin—hematologic cancer	3.27e-05	0.000126	CcSEcCtD
Ticagrelor—Asthenia—Etoposide—hematologic cancer	3.26e-05	0.000126	CcSEcCtD
Ticagrelor—Connective tissue disorder—Doxorubicin—hematologic cancer	3.26e-05	0.000126	CcSEcCtD
Ticagrelor—Body temperature increased—Triamcinolone—hematologic cancer	3.26e-05	0.000125	CcSEcCtD
Ticagrelor—Angiopathy—Epirubicin—hematologic cancer	3.25e-05	0.000125	CcSEcCtD
Ticagrelor—Urethral disorder—Doxorubicin—hematologic cancer	3.25e-05	0.000125	CcSEcCtD
Ticagrelor—Nausea—Mitoxantrone—hematologic cancer	3.24e-05	0.000125	CcSEcCtD
Ticagrelor—Nausea—Irinotecan—hematologic cancer	3.24e-05	0.000125	CcSEcCtD
Ticagrelor—Immune system disorder—Epirubicin—hematologic cancer	3.24e-05	0.000125	CcSEcCtD
Ticagrelor—Mediastinal disorder—Epirubicin—hematologic cancer	3.23e-05	0.000124	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.23e-05	0.000124	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.23e-05	0.000124	CcSEcCtD
Ticagrelor—Back pain—Methotrexate—hematologic cancer	3.22e-05	0.000124	CcSEcCtD
Ticagrelor—Fatigue—Dexamethasone—hematologic cancer	3.22e-05	0.000124	CcSEcCtD
Ticagrelor—Fatigue—Betamethasone—hematologic cancer	3.22e-05	0.000124	CcSEcCtD
Ticagrelor—Pruritus—Etoposide—hematologic cancer	3.21e-05	0.000124	CcSEcCtD
Ticagrelor—Shock—Prednisone—hematologic cancer	3.2e-05	0.000123	CcSEcCtD
Ticagrelor—Nervous system disorder—Prednisone—hematologic cancer	3.19e-05	0.000123	CcSEcCtD
Ticagrelor—Skin disorder—Prednisone—hematologic cancer	3.16e-05	0.000122	CcSEcCtD
Ticagrelor—Nausea—Gemcitabine—hematologic cancer	3.16e-05	0.000122	CcSEcCtD
Ticagrelor—Vomiting—Cisplatin—hematologic cancer	3.15e-05	0.000121	CcSEcCtD
Ticagrelor—Mental disorder—Epirubicin—hematologic cancer	3.14e-05	0.000121	CcSEcCtD
Ticagrelor—Rash—Cisplatin—hematologic cancer	3.13e-05	0.00012	CcSEcCtD
Ticagrelor—Dermatitis—Cisplatin—hematologic cancer	3.12e-05	0.00012	CcSEcCtD
Ticagrelor—Malnutrition—Epirubicin—hematologic cancer	3.12e-05	0.00012	CcSEcCtD
Ticagrelor—Diarrhoea—Etoposide—hematologic cancer	3.11e-05	0.00012	CcSEcCtD
Ticagrelor—Eye disorder—Doxorubicin—hematologic cancer	3.1e-05	0.000119	CcSEcCtD
Ticagrelor—Feeling abnormal—Betamethasone—hematologic cancer	3.08e-05	0.000119	CcSEcCtD
Ticagrelor—Feeling abnormal—Dexamethasone—hematologic cancer	3.08e-05	0.000119	CcSEcCtD
Ticagrelor—Cardiac disorder—Doxorubicin—hematologic cancer	3.08e-05	0.000119	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.06e-05	0.000118	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Betamethasone—hematologic cancer	3.06e-05	0.000118	CcSEcCtD
Ticagrelor—Hypersensitivity—Triamcinolone—hematologic cancer	3.03e-05	0.000117	CcSEcCtD
Ticagrelor—Back pain—Epirubicin—hematologic cancer	3.02e-05	0.000116	CcSEcCtD
Ticagrelor—Angiopathy—Doxorubicin—hematologic cancer	3.01e-05	0.000116	CcSEcCtD
Ticagrelor—Dizziness—Etoposide—hematologic cancer	3e-05	0.000116	CcSEcCtD
Ticagrelor—Immune system disorder—Doxorubicin—hematologic cancer	2.99e-05	0.000115	CcSEcCtD
Ticagrelor—Vertigo—Methotrexate—hematologic cancer	2.99e-05	0.000115	CcSEcCtD
Ticagrelor—Mediastinal disorder—Doxorubicin—hematologic cancer	2.99e-05	0.000115	CcSEcCtD
Ticagrelor—Dizziness—Prednisolone—hematologic cancer	2.96e-05	0.000114	CcSEcCtD
Ticagrelor—Asthenia—Triamcinolone—hematologic cancer	2.95e-05	0.000114	CcSEcCtD
Ticagrelor—Abdominal pain—Betamethasone—hematologic cancer	2.95e-05	0.000114	CcSEcCtD
Ticagrelor—Body temperature increased—Betamethasone—hematologic cancer	2.95e-05	0.000114	CcSEcCtD
Ticagrelor—Body temperature increased—Dexamethasone—hematologic cancer	2.95e-05	0.000114	CcSEcCtD
Ticagrelor—Abdominal pain—Dexamethasone—hematologic cancer	2.95e-05	0.000114	CcSEcCtD
Ticagrelor—Nausea—Cisplatin—hematologic cancer	2.94e-05	0.000113	CcSEcCtD
Ticagrelor—Paraesthesia—Prednisone—hematologic cancer	2.92e-05	0.000113	CcSEcCtD
Ticagrelor—Pruritus—Triamcinolone—hematologic cancer	2.91e-05	0.000112	CcSEcCtD
Ticagrelor—Cough—Methotrexate—hematologic cancer	2.91e-05	0.000112	CcSEcCtD
Ticagrelor—Mental disorder—Doxorubicin—hematologic cancer	2.9e-05	0.000112	CcSEcCtD
Ticagrelor—Vomiting—Etoposide—hematologic cancer	2.89e-05	0.000111	CcSEcCtD
Ticagrelor—Malnutrition—Doxorubicin—hematologic cancer	2.89e-05	0.000111	CcSEcCtD
Ticagrelor—Dyspepsia—Prednisone—hematologic cancer	2.86e-05	0.00011	CcSEcCtD
Ticagrelor—Rash—Etoposide—hematologic cancer	2.86e-05	0.00011	CcSEcCtD
Ticagrelor—Dermatitis—Etoposide—hematologic cancer	2.86e-05	0.00011	CcSEcCtD
Ticagrelor—Headache—Etoposide—hematologic cancer	2.84e-05	0.00011	CcSEcCtD
Ticagrelor—Chest pain—Methotrexate—hematologic cancer	2.84e-05	0.000109	CcSEcCtD
Ticagrelor—Rash—Prednisolone—hematologic cancer	2.82e-05	0.000109	CcSEcCtD
Ticagrelor—Dermatitis—Prednisolone—hematologic cancer	2.82e-05	0.000109	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.82e-05	0.000109	CcSEcCtD
Ticagrelor—Fatigue—Prednisone—hematologic cancer	2.81e-05	0.000108	CcSEcCtD
Ticagrelor—Headache—Prednisolone—hematologic cancer	2.81e-05	0.000108	CcSEcCtD
Ticagrelor—Vertigo—Epirubicin—hematologic cancer	2.8e-05	0.000108	CcSEcCtD
Ticagrelor—Syncope—Epirubicin—hematologic cancer	2.8e-05	0.000108	CcSEcCtD
Ticagrelor—Back pain—Doxorubicin—hematologic cancer	2.79e-05	0.000108	CcSEcCtD
Ticagrelor—Constipation—Prednisone—hematologic cancer	2.78e-05	0.000107	CcSEcCtD
Ticagrelor—Confusional state—Methotrexate—hematologic cancer	2.74e-05	0.000106	CcSEcCtD
Ticagrelor—Loss of consciousness—Epirubicin—hematologic cancer	2.74e-05	0.000106	CcSEcCtD
Ticagrelor—Dizziness—Triamcinolone—hematologic cancer	2.72e-05	0.000105	CcSEcCtD
Ticagrelor—Cough—Epirubicin—hematologic cancer	2.72e-05	0.000105	CcSEcCtD
Ticagrelor—Nausea—Etoposide—hematologic cancer	2.7e-05	0.000104	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—IL6R—hematologic cancer	2.7e-05	0.000466	CbGpPWpGaD
Ticagrelor—Hypertension—Epirubicin—hematologic cancer	2.69e-05	0.000104	CcSEcCtD
Ticagrelor—Feeling abnormal—Prednisone—hematologic cancer	2.68e-05	0.000103	CcSEcCtD
Ticagrelor—Asthenia—Betamethasone—hematologic cancer	2.68e-05	0.000103	CcSEcCtD
Ticagrelor—Asthenia—Dexamethasone—hematologic cancer	2.68e-05	0.000103	CcSEcCtD
Ticagrelor—ABCB1—Metabolism—SMPD3—hematologic cancer	2.68e-05	0.000463	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—TGFB1—hematologic cancer	2.67e-05	0.000461	CbGpPWpGaD
Ticagrelor—Nervous system disorder—Methotrexate—hematologic cancer	2.67e-05	0.000103	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Prednisone—hematologic cancer	2.66e-05	0.000103	CcSEcCtD
Ticagrelor—Nausea—Prednisolone—hematologic cancer	2.66e-05	0.000103	CcSEcCtD
Ticagrelor—Chest pain—Epirubicin—hematologic cancer	2.66e-05	0.000102	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3R1—hematologic cancer	2.65e-05	0.000459	CbGpPWpGaD
Ticagrelor—Pruritus—Betamethasone—hematologic cancer	2.64e-05	0.000102	CcSEcCtD
Ticagrelor—Pruritus—Dexamethasone—hematologic cancer	2.64e-05	0.000102	CcSEcCtD
Ticagrelor—Skin disorder—Methotrexate—hematologic cancer	2.64e-05	0.000102	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.64e-05	0.000102	CcSEcCtD
Ticagrelor—Vomiting—Triamcinolone—hematologic cancer	2.62e-05	0.000101	CcSEcCtD
Ticagrelor—Rash—Triamcinolone—hematologic cancer	2.6e-05	0.0001	CcSEcCtD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	2.6e-05	0.000449	CbGpPWpGaD
Ticagrelor—Dermatitis—Triamcinolone—hematologic cancer	2.59e-05	0.0001	CcSEcCtD
Ticagrelor—Vertigo—Doxorubicin—hematologic cancer	2.59e-05	9.99e-05	CcSEcCtD
Ticagrelor—Syncope—Doxorubicin—hematologic cancer	2.59e-05	9.97e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—hematologic cancer	2.59e-05	0.000447	CbGpPWpGaD
Ticagrelor—Headache—Triamcinolone—hematologic cancer	2.58e-05	9.94e-05	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—JAK2—hematologic cancer	2.58e-05	0.000446	CbGpPWpGaD
Ticagrelor—Abdominal pain—Prednisone—hematologic cancer	2.57e-05	9.91e-05	CcSEcCtD
Ticagrelor—Body temperature increased—Prednisone—hematologic cancer	2.57e-05	9.91e-05	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—KRAS—hematologic cancer	2.57e-05	0.000445	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—MAP2K1—hematologic cancer	2.57e-05	0.000444	CbGpPWpGaD
Ticagrelor—Confusional state—Epirubicin—hematologic cancer	2.57e-05	9.89e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—hematologic cancer	2.56e-05	0.000443	CbGpPWpGaD
Ticagrelor—Diarrhoea—Betamethasone—hematologic cancer	2.56e-05	9.85e-05	CcSEcCtD
Ticagrelor—Diarrhoea—Dexamethasone—hematologic cancer	2.56e-05	9.85e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—GRB2—hematologic cancer	2.56e-05	0.000442	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CD—hematologic cancer	2.55e-05	0.000441	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PDGFA—hematologic cancer	2.55e-05	0.000441	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—hematologic cancer	2.55e-05	0.000441	CbGpPWpGaD
Ticagrelor—Hypotension—Methotrexate—hematologic cancer	2.54e-05	9.79e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—hematologic cancer	2.54e-05	0.000439	CbGpPWpGaD
Ticagrelor—Loss of consciousness—Doxorubicin—hematologic cancer	2.54e-05	9.77e-05	CcSEcCtD
Ticagrelor—Cough—Doxorubicin—hematologic cancer	2.52e-05	9.7e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—KITLG—hematologic cancer	2.51e-05	0.000435	CbGpPWpGaD
Ticagrelor—Shock—Epirubicin—hematologic cancer	2.5e-05	9.65e-05	CcSEcCtD
Ticagrelor—Nervous system disorder—Epirubicin—hematologic cancer	2.5e-05	9.62e-05	CcSEcCtD
Ticagrelor—Hypertension—Doxorubicin—hematologic cancer	2.49e-05	9.6e-05	CcSEcCtD
Ticagrelor—ABCB1—Allograft Rejection—TNF—hematologic cancer	2.49e-05	0.000431	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—hematologic cancer	2.48e-05	0.000428	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—hematologic cancer	2.48e-05	0.000428	CbGpPWpGaD
Ticagrelor—Skin disorder—Epirubicin—hematologic cancer	2.47e-05	9.53e-05	CcSEcCtD
Ticagrelor—Dizziness—Dexamethasone—hematologic cancer	2.47e-05	9.52e-05	CcSEcCtD
Ticagrelor—Dizziness—Betamethasone—hematologic cancer	2.47e-05	9.52e-05	CcSEcCtD
Ticagrelor—Chest pain—Doxorubicin—hematologic cancer	2.46e-05	9.47e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—STAT5A—hematologic cancer	2.46e-05	0.000425	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CB—hematologic cancer	2.45e-05	0.000424	CbGpPWpGaD
Ticagrelor—Nausea—Triamcinolone—hematologic cancer	2.45e-05	9.43e-05	CcSEcCtD
Ticagrelor—Paraesthesia—Methotrexate—hematologic cancer	2.44e-05	9.41e-05	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.44e-05	9.4e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—CDKN2B—hematologic cancer	2.43e-05	0.000421	CbGpPWpGaD
Ticagrelor—Dyspnoea—Methotrexate—hematologic cancer	2.42e-05	9.35e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3R1—hematologic cancer	2.41e-05	0.000417	CbGpPWpGaD
Ticagrelor—Hypersensitivity—Prednisone—hematologic cancer	2.4e-05	9.24e-05	CcSEcCtD
Ticagrelor—Dyspepsia—Methotrexate—hematologic cancer	2.39e-05	9.23e-05	CcSEcCtD
Ticagrelor—Hypotension—Epirubicin—hematologic cancer	2.38e-05	9.17e-05	CcSEcCtD
Ticagrelor—Vomiting—Betamethasone—hematologic cancer	2.38e-05	9.16e-05	CcSEcCtD
Ticagrelor—Vomiting—Dexamethasone—hematologic cancer	2.38e-05	9.16e-05	CcSEcCtD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	2.38e-05	0.000411	CbGpPWpGaD
Ticagrelor—Confusional state—Doxorubicin—hematologic cancer	2.37e-05	9.15e-05	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—PIK3CA—hematologic cancer	2.36e-05	0.000409	CbGpPWpGaD
Ticagrelor—Rash—Betamethasone—hematologic cancer	2.36e-05	9.08e-05	CcSEcCtD
Ticagrelor—Rash—Dexamethasone—hematologic cancer	2.36e-05	9.08e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—CD86—hematologic cancer	2.36e-05	0.000407	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	2.35e-05	0.000407	CbGpPWpGaD
Ticagrelor—Dermatitis—Betamethasone—hematologic cancer	2.35e-05	9.07e-05	CcSEcCtD
Ticagrelor—Dermatitis—Dexamethasone—hematologic cancer	2.35e-05	9.07e-05	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.35e-05	9.05e-05	CcSEcCtD
Ticagrelor—Fatigue—Methotrexate—hematologic cancer	2.34e-05	9.04e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—JAK2—hematologic cancer	2.34e-05	0.000405	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—B3GAT1—hematologic cancer	2.34e-05	0.000405	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—DCK—hematologic cancer	2.34e-05	0.000405	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ASNS—hematologic cancer	2.34e-05	0.000405	CbGpPWpGaD
Ticagrelor—Headache—Dexamethasone—hematologic cancer	2.34e-05	9.02e-05	CcSEcCtD
Ticagrelor—Headache—Betamethasone—hematologic cancer	2.34e-05	9.02e-05	CcSEcCtD
Ticagrelor—Asthenia—Prednisone—hematologic cancer	2.33e-05	9e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—HES1—hematologic cancer	2.32e-05	0.000402	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	2.32e-05	0.000402	CbGpPWpGaD
Ticagrelor—Shock—Doxorubicin—hematologic cancer	2.32e-05	8.93e-05	CcSEcCtD
Ticagrelor—Nervous system disorder—Doxorubicin—hematologic cancer	2.31e-05	8.9e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—NCOR1—hematologic cancer	2.31e-05	0.000399	CbGpPWpGaD
Ticagrelor—Pruritus—Prednisone—hematologic cancer	2.3e-05	8.87e-05	CcSEcCtD
Ticagrelor—Skin disorder—Doxorubicin—hematologic cancer	2.29e-05	8.82e-05	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—TP53—hematologic cancer	2.29e-05	0.000395	CbGpPWpGaD
Ticagrelor—Paraesthesia—Epirubicin—hematologic cancer	2.29e-05	8.81e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—CSF2—hematologic cancer	2.28e-05	0.000395	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—FGF1—hematologic cancer	2.28e-05	0.000395	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—hematologic cancer	2.28e-05	0.000395	CbGpPWpGaD
Ticagrelor—Dyspnoea—Epirubicin—hematologic cancer	2.27e-05	8.75e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—FOXO1—hematologic cancer	2.25e-05	0.000389	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—IL2—hematologic cancer	2.25e-05	0.000389	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PDGFRB—hematologic cancer	2.25e-05	0.000389	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—NUP98—hematologic cancer	2.24e-05	0.000388	CbGpPWpGaD
Ticagrelor—Feeling abnormal—Methotrexate—hematologic cancer	2.24e-05	8.64e-05	CcSEcCtD
Ticagrelor—Dyspepsia—Epirubicin—hematologic cancer	2.24e-05	8.63e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—hematologic cancer	2.23e-05	0.000386	CbGpPWpGaD
Ticagrelor—Diarrhoea—Prednisone—hematologic cancer	2.23e-05	8.58e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CB—hematologic cancer	2.22e-05	0.000385	CbGpPWpGaD
Ticagrelor—Gastrointestinal pain—Methotrexate—hematologic cancer	2.22e-05	8.57e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—hematologic cancer	2.22e-05	0.000385	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—HDC—hematologic cancer	2.22e-05	0.000384	CbGpPWpGaD
Ticagrelor—Nausea—Dexamethasone—hematologic cancer	2.22e-05	8.55e-05	CcSEcCtD
Ticagrelor—Nausea—Betamethasone—hematologic cancer	2.22e-05	8.55e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—PDGFRA—hematologic cancer	2.21e-05	0.000383	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—JAK1—hematologic cancer	2.2e-05	0.000381	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PRKCG—hematologic cancer	2.2e-05	0.000381	CbGpPWpGaD
Ticagrelor—Hypotension—Doxorubicin—hematologic cancer	2.2e-05	8.48e-05	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.2e-05	8.47e-05	CcSEcCtD
Ticagrelor—Fatigue—Epirubicin—hematologic cancer	2.19e-05	8.46e-05	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—HRAS—hematologic cancer	2.19e-05	0.000378	CbGpPWpGaD
Ticagrelor—Constipation—Epirubicin—hematologic cancer	2.18e-05	8.39e-05	CcSEcCtD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	2.18e-05	0.000376	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	2.16e-05	0.000374	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—NUP214—hematologic cancer	2.16e-05	0.000374	CbGpPWpGaD
Ticagrelor—Dizziness—Prednisone—hematologic cancer	2.15e-05	8.29e-05	CcSEcCtD
Ticagrelor—Abdominal pain—Methotrexate—hematologic cancer	2.15e-05	8.29e-05	CcSEcCtD
Ticagrelor—Body temperature increased—Methotrexate—hematologic cancer	2.15e-05	8.29e-05	CcSEcCtD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—AKT1—hematologic cancer	2.14e-05	0.00037	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	2.13e-05	0.000369	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—hematologic cancer	2.12e-05	0.000367	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	2.12e-05	0.000366	CbGpPWpGaD
Ticagrelor—Paraesthesia—Doxorubicin—hematologic cancer	2.11e-05	8.15e-05	CcSEcCtD
Ticagrelor—Dyspnoea—Doxorubicin—hematologic cancer	2.1e-05	8.09e-05	CcSEcCtD
Ticagrelor—Feeling abnormal—Epirubicin—hematologic cancer	2.1e-05	8.08e-05	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Epirubicin—hematologic cancer	2.08e-05	8.02e-05	CcSEcCtD
Ticagrelor—Dyspepsia—Doxorubicin—hematologic cancer	2.07e-05	7.99e-05	CcSEcCtD
Ticagrelor—Vomiting—Prednisone—hematologic cancer	2.07e-05	7.97e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—IL2RA—hematologic cancer	2.06e-05	0.000356	CbGpPWpGaD
Ticagrelor—Rash—Prednisone—hematologic cancer	2.05e-05	7.91e-05	CcSEcCtD
Ticagrelor—Dermatitis—Prednisone—hematologic cancer	2.05e-05	7.9e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—IL2—hematologic cancer	2.04e-05	0.000353	CbGpPWpGaD
Ticagrelor—Headache—Prednisone—hematologic cancer	2.04e-05	7.86e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—TERT—hematologic cancer	2.04e-05	0.000352	CbGpPWpGaD
Ticagrelor—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.03e-05	7.84e-05	CcSEcCtD
Ticagrelor—Fatigue—Doxorubicin—hematologic cancer	2.03e-05	7.83e-05	CcSEcCtD
Ticagrelor—ABCB1—Metabolism—CDA—hematologic cancer	2.03e-05	0.000351	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—hematologic cancer	2.02e-05	0.000349	CbGpPWpGaD
Ticagrelor—Constipation—Doxorubicin—hematologic cancer	2.01e-05	7.76e-05	CcSEcCtD
Ticagrelor—Body temperature increased—Epirubicin—hematologic cancer	2.01e-05	7.75e-05	CcSEcCtD
Ticagrelor—Abdominal pain—Epirubicin—hematologic cancer	2.01e-05	7.75e-05	CcSEcCtD
Ticagrelor—Hypersensitivity—Methotrexate—hematologic cancer	2e-05	7.72e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—PDGFB—hematologic cancer	1.99e-05	0.000344	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PC—hematologic cancer	1.95e-05	0.000338	CbGpPWpGaD
Ticagrelor—Asthenia—Methotrexate—hematologic cancer	1.95e-05	7.52e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—TSC2—hematologic cancer	1.94e-05	0.000336	CbGpPWpGaD
Ticagrelor—Feeling abnormal—Doxorubicin—hematologic cancer	1.94e-05	7.48e-05	CcSEcCtD
Ticagrelor—Nausea—Prednisone—hematologic cancer	1.93e-05	7.45e-05	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—AKT1—hematologic cancer	1.93e-05	0.000334	CbGpPWpGaD
Ticagrelor—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.93e-05	7.42e-05	CcSEcCtD
Ticagrelor—Pruritus—Methotrexate—hematologic cancer	1.92e-05	7.42e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—hematologic cancer	1.92e-05	0.000332	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—hematologic cancer	1.89e-05	0.000327	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GBA—hematologic cancer	1.89e-05	0.000326	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—SLC35B2—hematologic cancer	1.89e-05	0.000326	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—TFRC—hematologic cancer	1.89e-05	0.000326	CbGpPWpGaD
Ticagrelor—Hypersensitivity—Epirubicin—hematologic cancer	1.88e-05	7.23e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—FGFR3—hematologic cancer	1.87e-05	0.000323	CbGpPWpGaD
Ticagrelor—Abdominal pain—Doxorubicin—hematologic cancer	1.86e-05	7.18e-05	CcSEcCtD
Ticagrelor—Body temperature increased—Doxorubicin—hematologic cancer	1.86e-05	7.18e-05	CcSEcCtD
Ticagrelor—Diarrhoea—Methotrexate—hematologic cancer	1.86e-05	7.17e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—MAPK14—hematologic cancer	1.85e-05	0.00032	CbGpPWpGaD
Ticagrelor—Asthenia—Epirubicin—hematologic cancer	1.83e-05	7.04e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—ESR1—hematologic cancer	1.81e-05	0.000314	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—FTCD—hematologic cancer	1.8e-05	0.000312	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PHYH—hematologic cancer	1.8e-05	0.000312	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GMPS—hematologic cancer	1.8e-05	0.000312	CbGpPWpGaD
Ticagrelor—Pruritus—Epirubicin—hematologic cancer	1.8e-05	6.94e-05	CcSEcCtD
Ticagrelor—Dizziness—Methotrexate—hematologic cancer	1.8e-05	6.93e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—FN1—hematologic cancer	1.79e-05	0.00031	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—BAD—hematologic cancer	1.77e-05	0.000306	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NFKBIA—hematologic cancer	1.77e-05	0.000306	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOTCH1—hematologic cancer	1.75e-05	0.000303	CbGpPWpGaD
Ticagrelor—Diarrhoea—Epirubicin—hematologic cancer	1.74e-05	6.71e-05	CcSEcCtD
Ticagrelor—Hypersensitivity—Doxorubicin—hematologic cancer	1.74e-05	6.69e-05	CcSEcCtD
Ticagrelor—Vomiting—Methotrexate—hematologic cancer	1.73e-05	6.66e-05	CcSEcCtD
Ticagrelor—ABCB1—Metabolism—MTAP—hematologic cancer	1.73e-05	0.000299	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	1.72e-05	0.000298	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CD80—hematologic cancer	1.72e-05	0.000297	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KIT—hematologic cancer	1.71e-05	0.000297	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CG—hematologic cancer	1.71e-05	0.000297	CbGpPWpGaD
Ticagrelor—Rash—Methotrexate—hematologic cancer	1.71e-05	6.61e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—NRAS—hematologic cancer	1.71e-05	0.000297	CbGpPWpGaD
Ticagrelor—Dermatitis—Methotrexate—hematologic cancer	1.71e-05	6.6e-05	CcSEcCtD
Ticagrelor—Headache—Methotrexate—hematologic cancer	1.7e-05	6.57e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	1.69e-05	0.000292	CbGpPWpGaD
Ticagrelor—Asthenia—Doxorubicin—hematologic cancer	1.69e-05	6.51e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—PTPN11—hematologic cancer	1.68e-05	0.000291	CbGpPWpGaD
Ticagrelor—Dizziness—Epirubicin—hematologic cancer	1.68e-05	6.49e-05	CcSEcCtD
Ticagrelor—Pruritus—Doxorubicin—hematologic cancer	1.67e-05	6.42e-05	CcSEcCtD
Ticagrelor—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.65e-05	0.000286	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	1.65e-05	0.000285	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—MAPK3—hematologic cancer	1.64e-05	0.000284	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	1.64e-05	0.000284	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CREB1—hematologic cancer	1.63e-05	0.000282	CbGpPWpGaD
Ticagrelor—Vomiting—Epirubicin—hematologic cancer	1.62e-05	6.24e-05	CcSEcCtD
Ticagrelor—Nausea—Methotrexate—hematologic cancer	1.62e-05	6.23e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—BRAF—hematologic cancer	1.61e-05	0.000279	CbGpPWpGaD
Ticagrelor—Diarrhoea—Doxorubicin—hematologic cancer	1.61e-05	6.21e-05	CcSEcCtD
Ticagrelor—Rash—Epirubicin—hematologic cancer	1.6e-05	6.19e-05	CcSEcCtD
Ticagrelor—Dermatitis—Epirubicin—hematologic cancer	1.6e-05	6.18e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—CCL2—hematologic cancer	1.6e-05	0.000276	CbGpPWpGaD
Ticagrelor—Headache—Epirubicin—hematologic cancer	1.59e-05	6.15e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—IL6R—hematologic cancer	1.59e-05	0.000275	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	1.59e-05	0.000275	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CREBBP—hematologic cancer	1.59e-05	0.000275	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	1.59e-05	0.000275	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—CYCS—hematologic cancer	1.58e-05	0.000274	CbGpPWpGaD
Ticagrelor—Dizziness—Doxorubicin—hematologic cancer	1.56e-05	6e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	1.55e-05	0.000269	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—FHL2—hematologic cancer	1.54e-05	0.000266	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MAP2K1—hematologic cancer	1.52e-05	0.000263	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	1.51e-05	0.000262	CbGpPWpGaD
Ticagrelor—Nausea—Epirubicin—hematologic cancer	1.51e-05	5.83e-05	CcSEcCtD
Ticagrelor—ABCB1—Metabolism—AGRN—hematologic cancer	1.51e-05	0.000261	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CD—hematologic cancer	1.51e-05	0.000261	CbGpPWpGaD
Ticagrelor—Vomiting—Doxorubicin—hematologic cancer	1.5e-05	5.77e-05	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CA—hematologic cancer	1.49e-05	0.000258	CbGpPWpGaD
Ticagrelor—Rash—Doxorubicin—hematologic cancer	1.48e-05	5.72e-05	CcSEcCtD
Ticagrelor—Dermatitis—Doxorubicin—hematologic cancer	1.48e-05	5.72e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—KRAS—hematologic cancer	1.48e-05	0.000255	CbGpPWpGaD
Ticagrelor—Headache—Doxorubicin—hematologic cancer	1.48e-05	5.69e-05	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	1.47e-05	0.000255	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—FGF2—hematologic cancer	1.44e-05	0.00025	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.44e-05	0.00025	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ASNS—hematologic cancer	1.44e-05	0.00025	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—DCK—hematologic cancer	1.44e-05	0.00025	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	1.43e-05	0.000248	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—IDH2—hematologic cancer	1.43e-05	0.000247	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—HMMR—hematologic cancer	1.43e-05	0.000247	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3R1—hematologic cancer	1.42e-05	0.000246	CbGpPWpGaD
Ticagrelor—Nausea—Doxorubicin—hematologic cancer	1.4e-05	5.39e-05	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—JAK2—hematologic cancer	1.38e-05	0.000239	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—HDC—hematologic cancer	1.37e-05	0.000237	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	1.36e-05	0.000235	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CA—hematologic cancer	1.36e-05	0.000235	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MDM2—hematologic cancer	1.35e-05	0.000234	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ARNTL—hematologic cancer	1.34e-05	0.000233	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	1.32e-05	0.000228	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	1.32e-05	0.000228	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MTOR—hematologic cancer	1.31e-05	0.000227	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CB—hematologic cancer	1.31e-05	0.000227	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CA9—hematologic cancer	1.31e-05	0.000226	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ACP5—hematologic cancer	1.31e-05	0.000226	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NCOR2—hematologic cancer	1.29e-05	0.000223	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—HRAS—hematologic cancer	1.25e-05	0.000217	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CDA—hematologic cancer	1.25e-05	0.000216	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CDKN1B—hematologic cancer	1.23e-05	0.000213	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—IDH1—hematologic cancer	1.23e-05	0.000213	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	1.23e-05	0.000213	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—AKT1—hematologic cancer	1.22e-05	0.000211	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	1.22e-05	0.000211	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTO1—hematologic cancer	1.22e-05	0.00021	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ABCC3—hematologic cancer	1.22e-05	0.00021	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—TXN—hematologic cancer	1.22e-05	0.00021	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CASP3—hematologic cancer	1.21e-05	0.000209	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—IL2—hematologic cancer	1.21e-05	0.000209	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PC—hematologic cancer	1.2e-05	0.000208	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—IL6—hematologic cancer	1.2e-05	0.000208	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—SPHK1—hematologic cancer	1.19e-05	0.000206	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CCND1—hematologic cancer	1.18e-05	0.000203	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—JUN—hematologic cancer	1.17e-05	0.000203	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GBA—hematologic cancer	1.16e-05	0.000201	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.16e-05	0.000201	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—UGT1A1—hematologic cancer	1.14e-05	0.000198	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CDKN1A—hematologic cancer	1.14e-05	0.000197	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PTEN—hematologic cancer	1.14e-05	0.000196	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.12e-05	0.000194	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—SLC22A1—hematologic cancer	1.11e-05	0.000192	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CRABP1—hematologic cancer	1.11e-05	0.000192	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MAPK8—hematologic cancer	1.11e-05	0.000192	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—AKT1—hematologic cancer	1.11e-05	0.000192	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ALOX5—hematologic cancer	1.08e-05	0.000188	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.08e-05	0.000187	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—EP300—hematologic cancer	1.08e-05	0.000187	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—MTAP—hematologic cancer	1.06e-05	0.000184	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SRC—hematologic cancer	1.05e-05	0.000182	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NUP98—hematologic cancer	1.05e-05	0.000182	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—VEGFA—hematologic cancer	1.03e-05	0.000177	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ADCY7—hematologic cancer	1.02e-05	0.000176	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NCOA3—hematologic cancer	1.02e-05	0.000176	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—STAT3—hematologic cancer	1.02e-05	0.000176	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NRAS—hematologic cancer	1.01e-05	0.000175	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NUP214—hematologic cancer	1.01e-05	0.000175	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ABCG2—hematologic cancer	9.91e-06	0.000172	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—MTR—hematologic cancer	9.91e-06	0.000172	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ENO2—hematologic cancer	9.72e-06	0.000168	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MAPK3—hematologic cancer	9.7e-06	0.000168	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—FHL2—hematologic cancer	9.48e-06	0.000164	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MYC—hematologic cancer	9.44e-06	0.000163	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTT1—hematologic cancer	9.43e-06	0.000163	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TGFB1—hematologic cancer	9.41e-06	0.000163	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—AGRN—hematologic cancer	9.3e-06	0.000161	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—SDC1—hematologic cancer	9.22e-06	0.000159	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	9.15e-06	0.000158	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	8.83e-06	0.000153	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—HMMR—hematologic cancer	8.81e-06	0.000152	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—IDH2—hematologic cancer	8.81e-06	0.000152	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KRAS—hematologic cancer	8.72e-06	0.000151	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ARNTL—hematologic cancer	8.29e-06	0.000143	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	8.26e-06	0.000143	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CA9—hematologic cancer	8.06e-06	0.000139	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ACP5—hematologic cancer	8.06e-06	0.000139	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CA—hematologic cancer	8.01e-06	0.000139	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NCOR2—hematologic cancer	7.96e-06	0.000138	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CD44—hematologic cancer	7.84e-06	0.000136	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NQO1—hematologic cancer	7.84e-06	0.000136	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TP53—hematologic cancer	7.75e-06	0.000134	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—IDH1—hematologic cancer	7.58e-06	0.000131	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ABCC3—hematologic cancer	7.49e-06	0.00013	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTO1—hematologic cancer	7.49e-06	0.00013	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—TXN—hematologic cancer	7.49e-06	0.00013	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYCS—hematologic cancer	7.42e-06	0.000128	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—HRAS—hematologic cancer	7.41e-06	0.000128	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—HSP90AA1—hematologic cancer	7.37e-06	0.000127	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—SPHK1—hematologic cancer	7.33e-06	0.000127	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—IL6—hematologic cancer	7.09e-06	0.000123	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—UGT1A1—hematologic cancer	7.05e-06	0.000122	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CRABP1—hematologic cancer	6.85e-06	0.000119	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—SLC22A1—hematologic cancer	6.85e-06	0.000119	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ALOX5—hematologic cancer	6.68e-06	0.000116	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—AKT1—hematologic cancer	6.54e-06	0.000113	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTP1—hematologic cancer	6.54e-06	0.000113	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NUP98—hematologic cancer	6.47e-06	0.000112	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ADCY7—hematologic cancer	6.28e-06	0.000109	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NCOA3—hematologic cancer	6.28e-06	0.000109	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NUP214—hematologic cancer	6.24e-06	0.000108	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ABCG2—hematologic cancer	6.11e-06	0.000106	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—MTR—hematologic cancer	6.11e-06	0.000106	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTM1—hematologic cancer	6.01e-06	0.000104	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NCOR1—hematologic cancer	6.01e-06	0.000104	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ENO2—hematologic cancer	5.99e-06	0.000104	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.81e-06	0.000101	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—SDC1—hematologic cancer	5.68e-06	9.82e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—MTHFR—hematologic cancer	5.31e-06	9.18e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NQO1—hematologic cancer	4.83e-06	8.35e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CD44—hematologic cancer	4.83e-06	8.35e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYCS—hematologic cancer	4.57e-06	7.9e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4.54e-06	7.85e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CG—hematologic cancer	4.46e-06	7.72e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CREBBP—hematologic cancer	4.14e-06	7.15e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.03e-06	6.97e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.92e-06	6.78e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ALB—hematologic cancer	3.87e-06	6.7e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.81e-06	6.59e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.7e-06	6.4e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.7e-06	6.4e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.7e-06	6.4e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CB—hematologic cancer	3.42e-06	5.91e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.27e-06	5.66e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PTEN—hematologic cancer	2.95e-06	5.11e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—EP300—hematologic cancer	2.82e-06	4.87e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.75e-06	4.75e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.55e-06	4.41e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.42e-06	4.18e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ALB—hematologic cancer	2.38e-06	4.13e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.28e-06	3.95e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.11e-06	3.64e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CA—hematologic cancer	2.08e-06	3.6e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PTEN—hematologic cancer	1.82e-06	3.15e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—EP300—hematologic cancer	1.74e-06	3e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—AKT1—hematologic cancer	1.7e-06	2.94e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.28e-06	2.22e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—AKT1—hematologic cancer	1.05e-06	1.81e-05	CbGpPWpGaD
